Remove tag ms-society
article thumbnail

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Pharmaceutical Technology

Multiple sclerosis (MS) is a primary autoimmune disease in which inflammation is a core contributor to the degeneration of the central nervous system (CNS), leading to neurological disability and affecting sensory, visual, motor, and autonomic systems. DMTs for MS have a high price tag, particularly in the US.

Marketing 246
article thumbnail

Grand Rounds August 25, 2023: Pragmatic Trial of an EHR Application to Display Real-time PRO Data: Successes and Challenges (Gabriela Schmajuk, MD, MS)

Rethinking Clinical Trials

   Speaker Gabriela Schmajuk, MD, MS Professor of Medicine UCSF and the San Francisco VA Slides Keywords Patient-Reported Outcomes, Rheumatoid Arthritis, EHR Key Points Clinicians rely on patient-related outcomes (PROs) to track disease and function over time in patients with rheumatoid arthritis (RA).

Trials 141
article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Pietro Sormanni, PhD, Group Leader, Royal Society University Research Fellow, Chemistry of Health, Yusuf Hamied Department of Chemistry, University of Cambridge, on: ‘Third-generation approaches of antibody discovery and optimisation’.

Protein 59